| Veröffentlichte Version Download ( PDF | 315kB) | Lizenz: Creative Commons Namensnennung 4.0 International |
Decreased protein binding of moxifloxacin in patients with sepsis?
Dorn, Christoph
, Nowak, Hartmuth, Weidemann, Caroline, Martini, Stefan, Zeitlinger, Markus, Adamzik, Michael und Kees, Frieder K.
(2017)
Decreased protein binding of moxifloxacin in patients with sepsis?
GMS Infectious Diseases 2017 (5), Doc03.
Veröffentlichungsdatum dieses Volltextes: 06 Apr 2018 06:40
Artikel
DOI zum Zitieren dieses Dokuments: 10.5283/epub.36969
Zusammenfassung
The mean (SD) unbound fraction of moxifloxacin in plasma from patients with severe sepsis or septic shock was determined by ultrafiltration to 85.5±3.0% (range 81.9 and 91.6%) indicating a decreased protein binding of moxifloxacin in this population compared with the value of 58–60% provided in the Summary of Product Characteristics. However, previous investigations neglected the influence of pH ...
The mean (SD) unbound fraction of moxifloxacin in plasma from patients with severe sepsis or septic shock was determined by ultrafiltration to 85.5±3.0% (range 81.9 and 91.6%) indicating a decreased protein binding of moxifloxacin in this population compared with the value of 58–60% provided in the Summary of Product Characteristics. However, previous investigations neglected the influence of pH and temperature on the protein binding of moxifloxacin. Maintaining physiological conditions (pH 7.4, 37°C) – as in the present study – the unbound fraction of moxifloxacin in plasma from healthy volunteers was 84%. In contrast, the unbound fraction of moxifloxacin was 77% at 4°C and 66–68% in unbuffered plasma or at pH 8.5 in fair agreement with previously published data. PK/PD parameters e.g. fAUC/MIC or ratios between interstitial fluid and free plasma concentrations, which were obtained assuming a protein binding rate of moxifloxacin of 40% or more, should be revised.
Alternative Links zum Volltext
Beteiligte Einrichtungen
Details
| Dokumentenart | Artikel | ||||
| Titel eines Journals oder einer Zeitschrift | GMS Infectious Diseases | ||||
| Verlag: | Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. | ||||
|---|---|---|---|---|---|
| Band: | 2017 | ||||
| Nummer des Zeitschriftenheftes oder des Kapitels: | 5 | ||||
| Seitenbereich: | Doc03 | ||||
| Datum | 3 Februar 2017 | ||||
| Institutionen | Chemie und Pharmazie > Institut für Pharmazie > Arbeitsgruppe Klinische Pharmazie (Dr. Dorn) | ||||
| Identifikationsnummer |
| ||||
| Stichwörter / Keywords | fluoroquinolone, unbound fraction, ultrafiltration, septic shock | ||||
| Dewey-Dezimal-Klassifikation | 600 Technik, Medizin, angewandte Wissenschaften > 615 Pharmazie | ||||
| Status | Veröffentlicht | ||||
| Begutachtet | Ja, diese Version wurde begutachtet | ||||
| An der Universität Regensburg entstanden | Ja | ||||
| URN der UB Regensburg | urn:nbn:de:bvb:355-epub-498968 | ||||
| Dokumenten-ID | 36969 |
Downloadstatistik
Downloadstatistik